Benitec Biopharma (NASDAQ:BNTC) Announces Earnings Results

Benitec Biopharma (NASDAQ:BNTC) released its quarterly earnings data on Friday. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.19, Zacks reports.

Benitec Biopharma Stock Up 12.3 %

Shares of Benitec Biopharma stock traded up $1.20 during trading on Friday, hitting $10.90. 29,958 shares of the stock traded hands, compared to its average volume of 31,536. The company has a fifty day moving average price of $11.38 and a two-hundred day moving average price of $10.21. Benitec Biopharma has a twelve month low of $2.75 and a twelve month high of $13.29.

Analysts Set New Price Targets

Several brokerages have recently issued reports on BNTC. Baird R W raised shares of Benitec Biopharma to a “strong-buy” rating in a report on Thursday, December 12th. Guggenheim restated a “buy” rating and issued a $17.00 target price on shares of Benitec Biopharma in a research report on Tuesday, December 3rd. HC Wainwright started coverage on Benitec Biopharma in a report on Monday, December 16th. They set a “buy” rating and a $28.00 price target on the stock. Robert W. Baird began coverage on Benitec Biopharma in a report on Friday, December 13th. They issued an “outperform” rating and a $30.00 price objective for the company. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Benitec Biopharma in a research note on Friday, October 18th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $24.43.

Insider Transactions at Benitec Biopharma

In related news, Director Suvretta Capital Management, L bought 42,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were acquired at an average price of $9.60 per share, with a total value of $403,200.00. Following the completion of the transaction, the director now owns 7,957,365 shares of the company’s stock, valued at $76,390,704. The trade was a 0.53 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.30% of the stock is currently owned by company insiders.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.